Home | Sitemap | Search | ContactA- A A+
   
 
    Public Member Support us  
 

IBCSG 35-07 (SOLE) 

A phase III trial evaluating the role of continuous letrozole versus intermittent letrozole following 4 to 6 years of prior adjuvant endocrine therapy for postmenopausal women with hormone-receptor positive, node-positive early stage breast cancer.

Study Of Letrozole Extension (SOLE)

DESIGN

please click on the picture to see a larger version

Results & Publications


Presentations

Publications

Publicationslist (November 2017)

 

Study Chairs
Dr. Marco Colleoni - Milano, Italy

Statisticians
Dr. Meredith Regan

Lead Trial Coordinator
Holly Shaw

Data Managers
Karolyn Scott, Monica Greco,  Adriana Karausch

IBCSG Data Management Center/FSTRF
4033 Maple Road
Amherst, New York 14226 USA
Phone: +1 716 834 0900
Fax: +1 716 833 3990
Email: ibcsg35_SOLE@fstrf.org

Date of Activation
November 8, 2007

Targeted Accrual
4800 patients

Final Accrual
4884 patients


Date of closure
October 8, 2012


Results Publications Results & Publications
Other Pathology


News

14.06.2020:
Save the date and join the IBCSG Pink Ladies! June 14, 2020

20.03.2020:
The next IBCSG Annual Meeting will take place in Barcelona Spain on March 20 and 21, 2020.       

11.11.2019:
New publications are available 

All News

 
  Print